Introduction
============

Treatment for pediatric acute myeloid leukemia (AML) involves multiple consecutive courses of intensive chemotherapy followed by periods of prolonged severe neutropenia with substantive infection risks. Current supportive care guidelines in the Children\'s Oncology Group (COG) Phase III AML trials recommend hospitalization for the duration of chemotherapy and associated marrow aplasia. However, a recent survey of pediatric supportive care practices suggests that up to one-third of pediatric AML patients are discharged early to outpatient management during postchemotherapy neutropenia [@b1]. While outpatient supportive care in this population has only been examined in a single study of 26 patients [@b2], several studies of adult AML patient populations suggest that outpatient management during neutropenia may be safe and feasible [@b1]--[@b11]. Early hospital discharge was associated with fewer febrile episodes [@b3],[@b11], reduced use of intravenous antibiotics [@b3],[@b5],[@b8],[@b9] and comparable mortality [@b2],[@b11]. The studies to date generally reported on a single institution, were limited by small sample sizes, did not adjust for potential confounding, or lacked an appropriate inpatient reference population. To address these limitations, we used data from a large nationally representative cohort of children with new onset AML assembled using the Pediatric Health Information System (PHIS) database [@b12]. Course-specific mortality and resource utilization in pediatric patients who were discharged postchemotherapy to outpatient management during neutropenia were compared to similar patients who remained hospitalized. Based on the aforementioned data in adult AML populations, we hypothesized that early discharge would be associated with fewer in-hospital days per chemotherapy course with no increase in inpatient mortality or resource utilization.

Methods
=======

Data source
-----------

PHIS is an administrative database that contains inpatient, emergency department, ambulatory surgery, and observation unit information from 46 not-for-profit, tertiary care pediatric hospitals representing 17 large metropolitan areas, and accounts for nearly half of all pediatric discharges in the United States [@b13]. Data include demographics, dates of service, discharge disposition, and daily inpatient billing data for medications, laboratory tests, imaging procedures, clinical services, and supplies. Patients are assigned a unique identifier which allows records to be linked longitudinally across admissions. Data are anonymized at the time of submission and subject to a number of reliability and validity checks before inclusion in the database. Data quality is assured through a joint effort between the Children\'s Hospital Association and participating hospitals.

Study population
----------------

The current study population was derived from a cohort of children treated for new onset AML previously assembled from PHIS data [@b12]. Briefly, patients with a discharge diagnosis for any myeloid or unspecified leukemia (International Classification of Diseases-9 codes 205.xx--208.xx) following an admission occurring from January 1999 through March 2010 were identified in the PHIS database. Those with a diagnosis for an alternative malignancy or an indication of bone marrow transplantation within 60 days of the first diagnosis admission were excluded. Daily pharmacy data for each patient were then manually reviewed and chemotherapy administration patterns were matched to conventional pediatric AML treatment regimens. Patients who did not receive induction chemotherapy consistent with AML therapy were excluded.

The match quality for each regimen was rated as perfect, excellent (i.e., deviation of only 1 day for any of the medications in the regimen), probable/identifiable (i.e., deviation of more than 1 day for any of the medications in the regimen), or unknown (i.e., regimen did not match any conventional AML regimen). For these analyses, course-specific cohorts were limited to patients who received standard chemotherapy defined as a perfect or excellent chemotherapy match to the following regimens: ADE (cytarabine, daunorubicin, etoposide, ±gemtuzumab) at induction courses, AE (cytarabine, etoposide) at Intensification I, and MA (mitoxantrone, cytarabine, ±gemtuzumab) at Intensification II. If a patient received chemotherapy that was inconsistent with the regimens defined above, the patient was excluded from the analyses for that course and any subsequent courses.

The population of patients at each treatment course was further restricted to those considered eligible for discharge postchemotherapy and prior to absolute neutrophil count (ANC) recovery based upon a review of daily hospital resource utilization data. Within a course, patients were considered discharge-eligible if there was no record of ICU-level care or blood culture from the first day of chemotherapy through the last day of chemotherapy plus 3 days and there was no record of vasopressor use or supplemental oxygen therapy within the 3 days after the last day of chemotherapy. As previously detailed [@b14], ICU-level care was defined by the occurrence-specific ICD-9-CM procedure codes or clinical resources considered a priori as a marker of ICU care, rather than by physical location.

Exposure
--------

For each patient, dates of initial discharge following the last day of chemotherapy administration were determined at each course. The timing of discharge relative to the last day of chemotherapy in a given course was calculated as the difference between the dates of discharge and the last chemotherapy administration. Discharges occurring within the 3 days after chemotherapy completion were categorized as "early discharge" while those discharged more than 3 days postchemotherapy completion and those not discharged before the start of the next treatment course were categorized as "standard discharge."

Outcomes
--------

Course-specific follow-up started 4 days after the last day of chemotherapy and continued until the earliest of the following: the start of the subsequent course defined as the first inpatient day on which chemotherapy was administered, death, or 50 days after commencement of chemotherapy. If patients were discharged and subsequently readmitted within the follow-up period, then data for these readmissions were included in the analyses.

Outcomes of interest included the total number of inpatient days, the number of days to the start of the next treatment course, inpatient case fatality, and receipt of any ICU-level care. Additionally, utilization rates of the following resources were documented during the follow-up period: antibiotic, antifungal, antiviral and vasopressor medications, parenteral nutrition, blood product replacement, and supplemental oxygen. Inpatient case fatality rates were calculated based on discharge status which is coded for each hospitalization. Daily billing data were used to identify patients receiving any ICU-level care and to assess rates of utilization for the individual resources specified above. Binary indicator variables were created for each of the resources to designate exposure on each inpatient day and were summed to obtain the total number of days exposed. Resource utilization rates were reported as days of use per 1000 inpatient days. Each of the outcome measures was compared within chemotherapy courses by discharge status (i.e., early discharge versus standard discharge). For the subpopulation of patients who were discharged early, rates and timing of first readmission relative to the start of follow-up were also computed.

Covariates
----------

Patient characteristics including age (categorized as \<1, 1 to \<5, 5 to \<10, 10 to \<15, and ≥15 years), sex, race (dichotomized as white, non-white), and insurance status at the start of each chemotherapy course (categorized as private, government, other) were ascertained from PHIS. A hospital-level variable representing a hospital\'s early discharge practice was created based on the overall proportion of patients discharged early across courses.

Statistical analyses
--------------------

Histograms of the timing of discharge relative to the completion of chemotherapy were plotted for each course. The frequencies of early discharge (*n*, %) were tabulated by course and patient characteristics and were compared using chi-squared tests. A plot of hospital-specific rates of early discharge was generated to assess variability in practice. Linear regression models were used to compare continuous outcomes, specifically the total number of inpatient days and days to next chemotherapy course, by discharge status. Course-specific case fatality rates (*n*, %) were compared for early versus standard discharge status using logistic regression methods which provide a reliable approximation of the risk ratio for binary outcome variables when the event of interest is sufficiently rare (i.e., incidence proportion \<10%) [@b15]. The odds ratio is a less reliable estimate of the corresponding risk ratio when the event of interest is more common. Thus, log-binomial regression methods were used to directly estimate the adjusted risk ratios (aRR) and corresponding 95% confidence intervals (CI) comparing occurrence of any ICU-level care by discharge status [@b16]. Poisson regression models with inpatient days as offset were used to estimate adjusted rate ratios (aIRR) and 95% CI comparing counts of the number of days of use for each resource by discharge status. The log of total number of inpatient days was included as an offset to account for the different observation periods for different subjects and a Pearson scale adjustment was employed to correct for possible overdispersion. All multivariate models were adjusted for the covariates defined above.

Results
=======

Study population
----------------

A flow chart depicting the assembly of the study population is presented in Figure[1](#fig01){ref-type="fig"}. The initial PHIS cohort included 1349 patients with new onset AML who were treated with ADE at Induction I. Of these patients approximately 72% (*n* = 966) met all inclusion criteria to be included in the current analyses for at least one treatment course and contributed a total of 2358 chemotherapy courses. Patient characteristics for this population are presented in Table[1](#tbl1){ref-type="table"}. Overall, there were no significant differences in baseline characteristics between early and standard discharge patients.

###### 

Baseline demographics of AML patients

                                    Discharge status                
  -------------------- ------------ ------------------ ------------ --------
  Age, *n* (%)                                                      0.8002
   \<1 years           118 (12.2)   29 (11.9)          89 (11.8)    
   1 to \<5 years      245 (25.4)   87 (35.8)          187 (24.8)   
   5 to \<10 years     162 (16.8)   132 (54.3)         117 (15.5)   
   10 to \<15 years    272 (28.2)   199 (81.9)         205 (27.2)   
   ≥15 years           199 (20.6)   243 (100)          155 (20.6)   
  Gender, *n* (%)                                                   0.2637
   Male                510 (52.8)   132 (54.3)         378 (50.2)   
   Female              486 (50.3)   111 (45.7)         375 (49.8)   
  Race, *n* (%)                                                     0.4671
   White               653 (67.6)   164 (67.5)         489 (64.9)   
   Non-white           343 (35.5)   79 (32.5)          264 (35.1)   
  Insurance, *n* (%)                                                0.1348
   Private             380 (39.3)   105 (43.2)         275 (36.5)   
   Public              426 (44.1)   99 (40.7)          327 (43.4)   
   Other               190 (19.7)   39 (16)            151 (20.1)   

Includes patients who were discharged early following one or more treatment courses.

Includes patients who were never discharged early.

![Flowchart depicting assembly of study population from established PHIS cohort of newly diagnosed pediatric acute myeloid leukemia patients. PHIS, Pediatric Health Information System database; AML, acute myeloid leukemia; ADE, cytarabine, daunorubicin, etoposide, ±gemtuzumab; AE, cytarabine and etoposide; MA, mitoxantrone, cytarabine, ±gemtuzumab.](cam40004-1356-f1){#fig01}

Distribution of timing of discharge after chemotherapy
------------------------------------------------------

Figure[2](#fig02){ref-type="fig"} illustrates the bimodal distribution of timing of discharge relative to the completion of chemotherapy at each course. A subset of patients were discharged within a few days of their last chemotherapy administration at each course, but most patients remained hospitalized with median times to discharge ranging from 15 to 23 days postchemotherapy completion across treatment courses (Table[2](#tbl2){ref-type="table"}). A small number of patients following each chemotherapy course remained hospitalized through the start of the next course; this was more common following Induction I (13.5%) than following later courses (2.3--4.5%).

###### 

Days to discharge, frequency of early discharge, and rate and timing of readmission after early discharge by treatment course

                                               Induction I (*N*=643)   Induction II (*N*=716)   Intensification I (*N*=614)   Intensification II (*N*=385)
  -------------------------------------------- ----------------------- ------------------------ ----------------------------- ------------------------------
  Days to discharge, median (range)            18 (0--49)              15 (0--36)               19 (0--38)                    23 (0--50)
  Early discharge, *n* (%)                     45 (7.0)                166 (23.2)               145 (23.6)                    83 (21.6)
   Readmission, *n* (%)                        38 (84.4)               124 (74.7)               100 (69.0)                    58 (69.9)
   Days to first readmission, median (range)   4.0 (1.0--15.0)         7.0 (1.0--24.0)          8.0 (1.0--29.0)               7.0 (2.0--13.0)

![Distribution of timing of discharge relative to the last day of chemotherapy for each course. The vertical red stippled line transects each plot at the study defined threshold for early discharge.](cam40004-1356-f2){#fig02}

Rates of early discharge
------------------------

The frequencies of early discharge along with rates and timing of readmission are presented in Table[2](#tbl2){ref-type="table"} by course. Rates of early discharge varied by course, with early discharge being significantly less likely following Induction I (7.0%) than following subsequent courses (21.6--23.6%; all *P* \< 0.0001). Readmission rates following early discharge were high and ranged from 69% to 84% across courses. Median time to first readmission was somewhat shorter for Induction I (4 days) compared to other courses (7--8 days) (all *P* \< 0.001).

Rates of early discharge by patient characteristics are presented in Table S1. Across courses, rates of early discharge did not differ significantly by age, sex or race. However, patients with public or private insurance had higher rates of early discharge than those with other types of coverage at Intensification I (29.6% and 23.1% versus 11.5%, *P* = 0.0008) and Intensification II (24.0% and 24.9% versus 5.9%, *P* = 0.0043). As illustrated in Figure[3](#fig03){ref-type="fig"}, hospital-specific rates of early discharge varied substantially ranging from 0% to 100%. There was little intrapatient variability in the timing of discharge between courses excluding Induction I. Among patients who were discharged early after Induction II, 83% were also discharged early following subsequent courses. Among those who remained in the hospital after Induction II, 93% were consistently managed as an inpatient for subsequent courses.

![Variation in rates of early discharge by hospital. Hospitals are numbered in order of decreasing rate of early discharge. The numbers above each bar indicate the number of courses contributed by the hospital.](cam40004-1356-f3){#fig03}

Comparison of outcomes by early versus standard discharge status
----------------------------------------------------------------

Comparisons of total inpatient days, inpatient mortality, ICU-level care, and time to the next course by discharge status are also presented in Table[3](#tbl3){ref-type="table"}. Despite high rates of readmission, patients discharged early experienced approximately 9--12 fewer inpatient days across treatment courses (all *P* \< 0.001). Mortality rates following each course were generally low (0--2%) and did not differ significantly by early versus standard discharge status. However, more early discharge patients required any ICU-level care (7.2--18.1%) compared to standard discharge patients (2.0--8.6%) across all chemotherapy courses with the exception of Induction I (aRR: 2.16, 95% CI: 1.50, 3.11). The proportion of patients requiring ICU-level care increased with successive courses from Induction II to Intensification II for both early (*P* = 0.011) and standard discharge (*P* \< 0.0001). Additionally, mean times to next treatment course were longer for intensification than induction courses (*P* \< 0.0001) but did not differ for early versus standard discharge patients.

###### 

Comparisons of total inpatient days, inpatient mortality, ICU-level care, and time to next course by discharge status

                                         Discharge status    Adjusted comparison[1](#tf3-2){ref-type="table-fn"}^,^[2](#tf3-3){ref-type="table-fn"}(95% CI)   *P*-value              Discharge status   Adjusted comparison[1](#tf3-2){ref-type="table-fn"}^,^[2](#tf3-3){ref-type="table-fn"}(95% CI)   *P*-value                             
  -------------------------------------- ------------------- ------------------------------------------------------------------------------------------------ ---------------------- ------------------ ------------------------------------------------------------------------------------------------ --------------- --------------------- ----------
  Total inpatient days, median (range)   11.0 (1--39)        20.0 (6--42)                                                                                     −9.2 (−11.2, −7.2)     \<0.0001           9.5 (1--42)                                                                                      18.0 (5--43)    −8.58 (−9.6, −7.6)    \<0.0001
  Inpatient mortality, *n* (%)           0 (0)               2 (0.30)                                                                                         NE                                        2 (1.2)                                                                                          3 (0.6)         2.79 (0.42, 18.6)     0.291
  ICU-level care, *n* (%)                2 (4.4)             22 (3.7)                                                                                         1.64 (0.38, 7.12)      0.507              12 (7.2)                                                                                         11 (2.0)        4.55 (2.00, 10.4)     0.0003
  Days to next course, mean (SD)         26.6 (9.0)          29.0 (9.1)                                                                                       −2.44 (−5.25, 0.36)    0.089              28.6 (9.8)                                                                                       29.5 (9.4)      −0.91 (−2.62, 0.80)   0.298
                                         Intensification I   Intensification II                                                                                                                                                                                                                                                                
  Total inpatient days, median (range)   10.0 (1--42)        22.0 (11--47)                                                                                    −11.6 (−12.8, −10.5)   \<0.0001           20.0 (1--56)                                                                                     28.0 (13--61)   −8.8 (−10.9, −6.7)    \<0.0001
  Inpatient mortality, *n* (%)           0                   0                                                                                                NE                                        2 (2.4)                                                                                          2 (0.7)         2.81 (0.36, 21.8)     0.323
  ICU-level care, *n* (%)                15 (10.3)           24 (5.1)                                                                                         2.29 (1.19, 4.42)      0.0132             15 (18.1)                                                                                        26 (8.6)        2.42 (1.26, 4.66)     0.0081
  Days to next course, mean (SD)         38.4 (38.3)         38.1 (29.5)                                                                                      1.04 (−5.60, 7.67)     0.759              49.6 (30.6)                                                                                      52.9 (33.2)     −2.28 (−11.2, 6.61)   0.614

CI, confidence interval; ICU, intensive care unit; SD, standard deviation; NE, not estimable.

Mean difference presented for total inpatient days and days to next course. Odds ratio presented for inpatient mortality. Risk ratio presented for ICU-level care.

Due to the small numbers of deaths crude associations are presented for inpatient mortality. All other comparisons are adjusted for patient age at diagnosis, race, sex, and insurance status.

Table[4](#tbl4){ref-type="table"} presents comparisons of resource utilization rates by discharge status for each treatment course. Rates of inpatient antibiotic utilization were consistently higher among patients discharged early than among those who remained hospitalized, with an average increase of 43% across courses (aIRR: 1.43, 95%:1.36, 1.51). Rates of vasopressor (aIRR: 4.85, 95% CI: 3.05, 7.71) and supplemental oxygen (aIRR: 2.88, 95% CI: 1.83, 4.52) utilization were also higher among early discharge patients compared to standard discharge patients across all treatment courses. Overall blood product replacement rates were elevated among those discharged early only for Induction I (aIRR: 1.29, 95% CI: 1.09, 1.54) and Intensification II (aIRR: 1.25, 95% CI: 1.12, 1.40) chemotherapy courses. Although utilization rates of antifungal agents overall were comparable for early and standard discharge patients, there was a trend toward greater use of amphotericin products in the early discharge group which was offset by greater use of other antifungal agents in the standard discharge group (Table S2). There were no significant differences in the rates of total parenteral nutrition and antiviral agent utilization between the early and standard discharge patients at any course.

###### 

Comparisons of resource utilization rates (per 1000 inpatient days) by discharge status for each treatment course

                         Discharge status                         Discharge status                                                       
  ---------------------- ------------------- -------------------- ---------------------------------------------------- -------- -------- ----------------------------------------------------
  Antibiotics            1698.0              1404.4               1.30 (1.13, 1.50)[\*](#tf4-2){ref-type="table-fn"}   1620.5   996.5    1.60 (1.46, 1.76)[\*](#tf4-2){ref-type="table-fn"}
  Antifungals            848.5               889.5                0.91 (0.74, 1.12)                                    814.8    857.4    0.97 (0.89, 1.07)
  Antivirals             70.7                145.6                0.59 (0.21, 1.62)                                    114.8    151.2    0.67 (0.39, 1.13)
  Vasopressors           27.6                5.2                  8.07 (3.50, 18.6)[\*](#tf4-2){ref-type="table-fn"}   32.7     6.8      4.54 (2.08, 9.89)[\*](#tf4-2){ref-type="table-fn"}
  Blood Products         298.8               246.5                1.29 (1.09, 1.54)[\*](#tf4-2){ref-type="table-fn"}   238.7    221.5    1.06 (0.94, 1.19)
   Platelets             206.1               179.5                1.32 (1.05, 1.66)[\*](#tf4-2){ref-type="table-fn"}   150.2    144.5    1.03 (0.88, 1.21)
   Packed RBC            135.2               105.7                1.30 (1.06, 1.59)[\*](#tf4-2){ref-type="table-fn"}   144.9    106.8    1.20 (1.06, 1.36)[\*](#tf4-2){ref-type="table-fn"}
   FFP                   6.8                 4.9                  1.41 (0.44, 4.56)                                    12.4     3.3      3.03 (1.23, 7.48)[\*](#tf4-2){ref-type="table-fn"}
  Parenteral Nutrition   111.4               169.8                1.00 (0.50, 2.01)                                    86.2     84.8     1.28 (0.76, 2.14)
  Oxygen therapy         40.9                13.3                 5.14 (1.96, 13.5)[\*](#tf4-2){ref-type="table-fn"}   32.2     8.7      3.63 (1.79, 7.36)[\*](#tf4-2){ref-type="table-fn"}
                         Intensification I   Intensification II                                                                          
  Antibiotics            1589.9              1030.4               1.52 (1.39, 1.67)[\*](#tf4-2){ref-type="table-fn"}   1862.1   1357.5   1.36 (1.25, 1.49)[\*](#tf4-2){ref-type="table-fn"}
  Antifungals            775.3               853.1                0.93 (0.84, 1.03)                                    882.9    915.9    0.96 (0.87, 1.07)
  Antivirals             116.2               170.1                0.70 (0.41, 1.19)                                    109.0    165.4    0.62 (0.32, 1.21)
  Vasopressors           40.6                9.2                  5.67 (2.63, 12.2)[\*](#tf4-2){ref-type="table-fn"}   45.7     14.0     3.56 (1.65, 7.66)[\*](#tf4-2){ref-type="table-fn"}
  Blood products         259.3               228.7                1.17 (0.99, 1.38)                                    383.1    319.6    1.25 (1.12, 1.40)[\*](#tf4-2){ref-type="table-fn"}
   Platelets             168.3               154.5                1.21 (0.96, 1.52)                                    287.0    244.2    1.26 (1.09, 1.46)[\*](#tf4-2){ref-type="table-fn"}
   Packed RBC            151.4               109.6                1.42 (1.18, 1.72)[\*](#tf4-2){ref-type="table-fn"}   171.5    133.8    1.32 (1.11, 1.56)[\*](#tf4-2){ref-type="table-fn"}
   FFP                   5.6                 2.2                  4.31 (1.61, 11.5)[\*](#tf4-2){ref-type="table-fn"}   8.6      5.5      1.72 (0.56, 5.25)[\*](#tf4-2){ref-type="table-fn"}
  Parenteral Nutrition   73.7                99.4                 1.22 (0.75, 1.98)                                    109.0    88.3     1.23 (0.82, 1.85)
  Oxygen Therapy         40.0                18.3                 2.22 (1.10, 4.51)[\*](#tf4-2){ref-type="table-fn"}   46.3     16.2     2.85 (1.39, 5.83)[\*](#tf4-2){ref-type="table-fn"}

All comparisons adjusted for patient age at diagnosis, race, sex, and insurance status at start of course. aIRR, adjusted rate ratio; CI, confidence interval; RBC, red blood cells; FFP, fresh frozen plasma.

*P* \< 0.05.

Discussion
==========

Our study found that pediatric AML patients who were discharged early following induction and intensification chemotherapy courses had similar course-specific survival, fewer days of hospitalization, and no apparent delay in progression to subsequent treatment courses compared to standard discharge patients. However, early discharge patients were frequently readmitted and had higher rates of antibiotic, vasopressor, and supplemental oxygen utilization than patients who remained hospitalized. Together these findings suggest that early discharge patients may have an increased risk for life-threatening infectious complications compared to standard discharge patients, but they are successfully treated upon readmission.

We observed significant variability in practice across hospitals with respect to postchemotherapy neutropenia management strategies. For some hospitals the majority of patients were identified as early discharge patients, while others maintained hospitalization for most, if not all, AML patients. This variation in practice is consistent with a recent survey of supportive care approaches among COG institutions [@b1] and likely reflects the dearth of studies to compare the effectiveness of the two strategies in pediatric AML populations. One pediatric study found similar rates of mortality for outpatient versus inpatient management of neutropenia following AML induction chemotherapy [@b2] which is consistent with our findings. Another study evaluating outpatient versus inpatient AML intensification chemotherapy found fewer days of febrile neutropenia and less antimicrobial use among outpatients than children receiving inpatient treatment [@b17]. Likewise, previous evaluations among adult AML patients found outpatient supportive care to be associated with fewer and shorter febrile episodes [@b5],[@b9] and fewer days of intravenous antibiotic administration [@b3],[@b5],[@b9]. The findings with respect to antimicrobial agent use contradict those of the current study. However, these previous studies have had a number of limitations which may have resulted in biased associations: most included data from only a single institution, had small sample sizes, lacked an internal reference or used an inpatient reference population which included patients too ill to be discharged, or did not adjust resource use comparisons for differences in duration of hospitalization between compared groups.

Our study has several strengths over the previous pediatric and adult publications. Our analysis was performed using a large nationally representative cohort of pediatric AML patients, increasing the generalizability of our results over small single institution studies. Also, unlike most previous evaluations, we restricted our comparison of early versus standard discharge to include only AML patients that met eligibility criteria for early discharge at the time of completion of chemotherapy. In the absence of this restriction, the standard discharge reference population would likely include patients with poorer baseline risk than those actually discharged to outpatient supportive care which would lead to biased comparisons.

Despite the strengths of the study, our results should be considered in light of some potential limitations. Billing data on resource utilization rather than medical record data were used to identify patients as discharge-eligible. Thus, it is possible that some higher risk patients who were not actually eligible for early discharge were retained in the analyzed cohort. However, more of these patients would likely be included in the standard than the early discharge group, which would bias observed associations toward no effect. The classification of early discharge was not informed by ANC measurements, but the threshold for early discharge was 3 days after completing chemotherapy; neutrophil recovery within this timeframe is improbable. Therefore, it is expected that all early discharge patients were neutropenic at the time of discharge. We also restricted the study population to patients whose chemotherapy courses were reliably matched to conventional AML regimens, which would further minimize bias in the classification of relative timing of discharge. We may also be missing information on resource utilization if patients were readmitted after being discharged to a hospital other than the one in which chemotherapy was delivered or if outpatient rather than inpatient resources were utilized. This pattern of missing data is likely differential leading to a greater underestimate of resource utilization in the early discharge patients than the standard discharge patients, suggesting that the increases observed following early discharge for some of the resources may be conservative estimates. Since our data were limited to inpatient resource utilization, we were unable to ascertain whether patients discharged early were prescribed antibacterial prophylaxis. Previous data suggest that a limited number of institutions utilize prophylactic antibiotics in patients with AML [@b1], thus we expect the proportion of patients to be similarly low (\<13%) in the current study population. Others have reported reduced infection rates with intravenous versus oral or no prophylactic antibiotic administration among pediatric AML patients discharged after chemotherapy to outpatient management during neutropenia [@b18]. Thus, it is possible that the detrimental effects that we observed in relation to early discharge may be attenuated among those patients utilizing such antibacterial prophylaxis. Increased rates of ICU-level care, antibiotic, vasopressor and supplemental oxygen utilization were assumed to be a marker for an increased incidence of clinically relevant infection in the early discharge patients. The absence of clinical and laboratory data for infection did not allow for confirmation of this assumption.

In summary, these data suggest that outpatient supportive care achieves fewer inpatient days per course and similar course-specific survival relative to inpatient supportive care. However, patients discharged early to outpatient management during neutropenia may be at greater risk for infectious complications that upon readmission require more intensive care resources for effective management. Additional work is required to ascertain the specific microbiological organisms involved, to compare the costs of early versus standard discharge strategies, and to assess patient and caregiver preferences about the respective advantages and disadvantages of the two strategies of postchemotherapy neutropenia management.
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Rates of early discharge by patient characteristics.

**Table S2.** Comparisons of resource utilization rates (per 1000 inpatient days) by discharge status for each treatment course.
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